Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026)
Nuvalent (NUVL) posted Liabilities and Shareholders Equity of $1.3 billion for Q1 2026, down 5.77% on a QoQ basis from $1.4 billion in Q4 2025, and up 20.38% year-over-year from $1.1 billion in Q1 2025.
Nuvalent (NUVL) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Nuvalent's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 20.38% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 15.87% YoY) and the FY2025 annual result came in at $1.4 billion, up 23.73% from the prior year.
- Liabilities and Shareholders Equity was $1.3 billion for Q1 2026 at Nuvalent, down from $1.4 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2025 and bottomed at $249.6 million in Q3 2022.
- A 5-year average of $759.8 million and a median of $708.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 18.97% — and 2024, when it jumped 179.68%.
- Nuvalent's Liabilities and Shareholders Equity stood at $482.5 million in 2022, then jumped by 51.8% to $732.4 million in 2023, then surged by 55.9% to $1.1 billion in 2024, then climbed by 23.73% to $1.4 billion in 2025, then dropped by 5.77% to $1.3 billion in 2026.
- Business Quant data shows NUVL's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $979.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 1.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.33 Bn |
| Dec 31, 2025 | 1.41 Bn |
| Sep 30, 2025 | 979.91 Mn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.11 Bn |
| Dec 31, 2024 | 1.14 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 675.23 Mn |
| Mar 31, 2024 | 708.47 Mn |
| Dec 31, 2023 | 732.38 Mn |
| Sep 30, 2023 | 425.08 Mn |
| Jun 30, 2023 | 441.95 Mn |
| Mar 31, 2023 | 460.99 Mn |
| Dec 31, 2022 | 482.46 Mn |
| Sep 30, 2022 | 249.56 Mn |
| Jun 30, 2022 | 263.02 Mn |
| Mar 31, 2022 | 277.04 Mn |
| Dec 31, 2021 | 293.82 Mn |
| Sep 30, 2021 | 307.97 Mn |
| Jun 30, 2021 | 143.50 Mn |